Immunomedics reports Phase II data

IMMU reported preliminary data from 44 patients in a 70-patient U.S. study, showing that 60 percent of patients with low-grade, non-Hodgkin's lymphoma (NHL) given IMMU's epratuzumab at the optimal wee...